Loading
A phase 2 trial of Calderasib, Pembrolizumab, Cetuximab and Sacituzumab tirumotecan in advanced solid tumours, run by Merck Sharp & Dohme LLC, now recruiting.
KEYMAKER-U01 Substudy 01J: A Study of Pembrolizumab Plus MK-1084 in Participants With Non-Small Cell Lung Cancer (NSCLC) With Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) G12C Mutations (MK-3475-01J/KEYMAKER-U01J) is a phase 2 interventional study registered as NCT07252739 by Merck Sharp & Dohme LLC, with 140 participants planned, started 2025-12-19 and due to reach its primary completion in 2029-11-15. Interventions recorded: MK-1084, Pembrolizumab, Cetuximab, Sacituzumab tirumotecan (sac-TMT) and Rescue medication.
Shares Calderasib, Sacituzumab tirumotecan, Cetuximab, Merck & Co. (MSD) and the tag pipeline.
Shares Calderasib, Cetuximab, Merck & Co. (MSD), Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Merck & Co. (MSD), Metastatic cancer (cancer that has spread), Pembrolizumab, Immune checkpoint inhibitors and the tag pipeline.
Shares Merck & Co. (MSD), Metastatic cancer (cancer that has spread), Pembrolizumab, Immune checkpoint inhibitors and the tag pipeline.
Shares Merck & Co. (MSD), Metastatic cancer (cancer that has spread), Pembrolizumab, Immune checkpoint inhibitors and the tag pipeline.
Shares Merck & Co. (MSD), Metastatic cancer (cancer that has spread), Pembrolizumab, Immune checkpoint inhibitors and the tag pipeline.
Shares Merck & Co. (MSD), Metastatic cancer (cancer that has spread), Pembrolizumab, Immune checkpoint inhibitors and the tag pipeline.
Shares Sacituzumab tirumotecan, Merck & Co. (MSD), Metastatic cancer (cancer that has spread), Pembrolizumab and the tag pipeline.